Sensitivity of the modified Children's Yale-Brown Obsessive Compulsive Scale to detect change: Results from two multi-site trials

TY - JOUR

T1 - Sensitivity of the modified Children's Yale-Brown Obsessive Compulsive Scale to detect change

T2 - Results from two multi-site trials

AU - Scahill, Lawrence

AU - Sukhodolsky, Denis G.

AU - Anderberg, Emily

AU - Dimitropoulos, Anastasia

AU - Dziura, James

AU - Aman, Michael G.

AU - McCracken, James

AU - Tierney, Elaine

AU - Hallett, Victoria

AU - Katz, Karol

AU - Vitiello, Benedetto

AU - McDougle, Christopher

PY - 2016/2/1

Y1 - 2016/2/1

N2 - Repetitive behavior is a core feature of autism spectrum disorder. We used 8-week data from two federally funded, multi-site, randomized trials with risperidone conducted by the Research Units on Pediatric Psychopharmacology Autism Network to evaluate the sensitivity of the Children's Yale-Brown Obsessive Compulsive Scale modified for autism spectrum disorder to detect change with treatment. Study 1 included 52 subjects assigned to placebo and 49 subjects to risperidone under double-blind conditions. In Study 2, 49 subjects received risperidone only and 75 subjects received risperidone plus parent training. The combined sample consisted of 187 boys and 38 girls (aged 4-17 years). At the medication-free baseline, the internal consistency on the Children's Yale-Brown Obsessive Compulsive Scale modified for autism spectrum disorder total score was excellent (Cronbach's alpha = 0.84) and the mean scores were similar across the four groups. Compared to placebo in Study 1, all three active treatment groups showed significant improvement (effect sizes: 0.74-0.88). There were no differences between active treatment groups. These results indicate that the Children's Yale-Brown Obsessive Compulsive Scale modified for autism spectrum disorder has acceptable test-retest as evidenced by the medium to high correlations in the placebo group and demonstrated sensitivity to change with treatment.

AB - Repetitive behavior is a core feature of autism spectrum disorder. We used 8-week data from two federally funded, multi-site, randomized trials with risperidone conducted by the Research Units on Pediatric Psychopharmacology Autism Network to evaluate the sensitivity of the Children's Yale-Brown Obsessive Compulsive Scale modified for autism spectrum disorder to detect change with treatment. Study 1 included 52 subjects assigned to placebo and 49 subjects to risperidone under double-blind conditions. In Study 2, 49 subjects received risperidone only and 75 subjects received risperidone plus parent training. The combined sample consisted of 187 boys and 38 girls (aged 4-17 years). At the medication-free baseline, the internal consistency on the Children's Yale-Brown Obsessive Compulsive Scale modified for autism spectrum disorder total score was excellent (Cronbach's alpha = 0.84) and the mean scores were similar across the four groups. Compared to placebo in Study 1, all three active treatment groups showed significant improvement (effect sizes: 0.74-0.88). There were no differences between active treatment groups. These results indicate that the Children's Yale-Brown Obsessive Compulsive Scale modified for autism spectrum disorder has acceptable test-retest as evidenced by the medium to high correlations in the placebo group and demonstrated sensitivity to change with treatment.

KW - autism spectrum disorder

KW - clinical trials

KW - outcome measurement

KW - repetitive behavior

KW - risperidone

UR - https://www.scopus.com/pages/publications/84954243208

U2 - 10.1177/1362361315574889

DO - 10.1177/1362361315574889

M3 - Article

AN - SCOPUS:84954243208

SN - 1362-3613

VL - 20

SP - 145

EP - 152

JO - Autism

JF - Autism

IS - 2

ER -